リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients

Jo, Tomoyasu Arai, Yasuyuki Kondo, Tadakazu Mizuno, Shohei Hirabayashi, Shigeki Inamoto, Yoshihiro Doki, Noriko Fukuda, Takahiro Ozawa, Yukiyasu Katayama, Yuta Kanda, Yoshinobu Fukushima, Kentaro Matsuoka, Ken-Ichi Takada, Satoru Sawa, Masashi Ashida, Takashi Onizuka, Makoto Ichinohe, Tatsuo Atsuta, Yoshiko Kanda, Junya Yanada, Masamitsu 京都大学 DOI:10.1016/j.jcyt.2022.05.009

2022.10

概要

[Background aims] In allogeneic stem cell transplantation, unrelated donors are chosen in cases where appropriate related donors are not available. Peripheral blood stem cells (PBSCs) are more often selected as a graft source than bone marrow (BM). However, the prognostic benefits of PBSCs versus BM transplants from unrelated donors have not been carefully examined in patients with acute myeloid leukemia (AML). This study compared outcomes of adult AML patients who underwent unrelated PBSC and BM transplantation, evaluating post-transplant complications, including engraftment, graft-versus-host disease (GVHD) and infections, and determined subgroups of patients who are most likely to benefit from unrelated PBSCs compared with BM transplants. [Methods] The authors analyzed 2962 adult AML patients who underwent unrelated PBSC or BM transplants between 2011 and 2018 (221 PBSC and 2741 BM) using the Japanese nationwide registry database, in which graft source selection is not skewed toward PBSCs. [Results] In 49.7% of patients, disease status at transplantation was first complete remission (CR1). In 57.1% of cases, HLA-matched donors were selected. Myeloablative conditioning was performed in 75.1% of cases, and anti-thymocyte globulin (ATG) was added to conditioning in 10.5%. Multivariate analyses showed a trend toward favorable non-relapse mortality (NRM) in PBSC recipients compared with BM recipients (hazard ratio [HR], 0.731, P = 0.096), whereas overall survival (OS) (HR, 0.959, P = 0.230) and disease-free survival (DFS) (HR, 0.868, P = 0.221) were comparable between PBSC and BM recipients. Although the rate of chronic GVHD (cGVHD) was significantly higher in PBSC patients (HR, 1.367, P = 0.016), NRM was not increased, mainly as a result of significantly reduced risk of bacterial infections (HR, 0.618, P = 0.010), reflecting more prompt engraftments in PBSC recipients. Subgroup analyses revealed that PBSC transplantation was advantageous in patients transplanted at CR1 and in those without ATG use. PBSC recipients experienced significantly better OS and/or DFS compared with BM recipients in this patient group. [Conclusions] The authors' results confirmed the overall safety of unrelated PBSC transplantation for adult AML patients and suggested an advantage of PBSCs, especially for those in CR1. Further optimization of the prophylactic strategy for cGVHD is required to improve the overall outcome in transplantation from unrelated PBSC donors.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

[1] Gale RP, Champlin RE. How does bone-marrow transplantation cure leukaemia? Lancet 1984;2(8393):28–30.

[2] Arai Y, Konuma T, Yanada M. Hematopoietic cell transplantation in adults with acute myeloid leukemia: A review of the results from various nationwide registry studies in Japan. Blood Cell Therapy 2021;4(2):35–43.

[3] Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2020. https://www.cibmtr.org/ ReferenceCenter/SlidesReports/SummarySlides/pages/index.aspx.

[4] Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med 2012;367(16):1487–96.

[5] Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant 2021;56(7):1651–64.

[6] Rowley SD, Donaldson G, Lilleby K, Bensinger WI, Appelbaum FR. Experiences of donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell transplantation. Blood 2001;97(9):2541–8.

[7] Karlsson L, Quinlan D, Guo D, et al. Mobilized blood cells vs bone marrow harvest: experience compared in 171 donors with particular reference to pain and fatigue. Bone Marrow Transplant 2004;33(7):709–13.

[8] Eapen M, Logan BR, Confer DL, et al. Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. Biol Blood Marrow Transplant 2007;13(12):1461–8.

[9] Eapen M, Logan BR, Appelbaum FR, et al. Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. Biol Blood Marrow Transplant 2015;21(1):55–9.

[10] D'Souza A, Fretham C, Lee SJ, et al. Current Use of and Trends in Hematopoietic Cell Transplantation in the United States. Biol Blood Marrow Transplant 2020;26 (8):e177–82.

[11] Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia 2015;29(10):2062–8.

[12] Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood 2017;130(21):2243–50.

[13] Nava T, Ansari M, Dalle JH, et al. Supportive care during pediatric hematopoietic stem cell transplantation: beyond infectious diseases. A report from workshops on supportive care of the Pediatric Diseases Working Party (PDWP) of the Euro- pean Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Trans- plant 2020;55(6):1126–36.

[14] Hematopoietic Cell Transplantation in Japan. Annual Report of Nationwide Survey 2020: The Japanese Data Center for Hematopoietic Cell Transplantation/The Japan Society for Hematopoietic. Cell Transplantation. http://www.jdchct.or.jp/data/ report/2020/

[15] Goto T, Tanaka T, Sawa M, et al. Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan. Int J Hematol 2018;107(2):211–21.

[16] Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA- related data). Int J Hematol 2016;103(1):3–10.

[17] Kanda J. Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation. Int J Hematol 2016;103(1):11–9.

[18] Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991;28(3):250–9.

[19] Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995;15(6):825–8.

[20] Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplanta- tion. Blood 2015;125(8):1333–8.

[21] De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal dis- ease from the European Organization for Research and Treatment of Cancer/Inva- sive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46(12):1813–21.

[22] Yanada M, Mori J, Aoki J, et al. Effect of cytogenetic risk status on outcomes for patients with acute myeloid leukemia undergoing various types of allogeneic hematopoietic cell transplantation: an analysis of 7812 patients. Leuk Lymphoma 2018;59(3):601–9.

[23] Giralt S, Ballen K, Rizzo D, et al. Reduced-intensity conditioning regimen work- shop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009;15(3):367–9.

[24] Morishima Y, Sasazuki T, Inoko H, et al. The clinical significance of human leuko- cyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B, and HLA-DR matched unrelated donors. Blood 2002;99(11):4200–6.

[25] Eapen M, Logan BR, Horowitz MM, et al. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol 2015;33(4):364–9.

[26] Worel N, Buser A, Greinix HT, et al. Suitability Criteria for Adult Related Donors: A Consensus Statement from the Worldwide Network for Blood and Marrow Trans- plantation Standing Committee on Donor Issues. Biol Blood Marrow Transplant 2015;21(12):2052–60.

[27] Nagafuji K, Matsuo K, Teshima T, et al. Peripheral blood stem cell versus bone marrow transplantation from HLA-identical sibling donors in patients with leuke- mia: a propensity score-based comparison from the Japan Society for Hematopoi- etic Stem Cell Transplantation registry. Int J Hematol 2010;91(5):855–64.

[28] Yanada M, Konuma T, Yamasaki S, et al. Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant 2020;26 (2):307–15.

[29] Young JH, Logan BR, Wu J, et al. Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. Biol Blood Marrow Trans- plant 2016;22(2):359–70.

[30] Laskin BL, Goebel J, Davies SM, Jodele S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 2011;118(6):1452–62.

[31] Poutsiaka DD, Munson D, Price LL, Chan GW, Snydman DR. Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated. Bone Mar- row Transplant 2011;46(2):300–7.

[32] Dalle JH, Giralt SA. Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: Risk Factors and Stratification, Prophylaxis, and Treatment. Biol Blood Marrow Transplant 2016;22(3):400–9.

[33] Noguchi M, Inagaki J. Hemophagocytic Lymphohistiocytosis and Graft Failure Fol- lowing Unrelated Umbilical Cord Blood Transplantation in Children. J Pediatr Hematol Oncol 2020;42(6):e440–4.

[34] Savani BN, Labopin M, Blaise D, et al. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica 2016;101(2):256–62.

[35] Kanda J, Brazauskas R, Hu ZH, et al. Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biol Blood Marrow Trans- plant 2016;22(4):744–51.

[36] Lee SJ, Logan B, Westervelt P, et al. Comparison of Patient-Reported Outcomes in 5-Year Survivors Who Received Bone Marrow vs Peripheral Blood Unrelated Donor Transplantation: Long-term Follow-up of a Randomized Clinical Trial. JAMA Oncol 2016;2(12):1583–9.

[37] Byrne M, Savani BN, Mohty M, Nagler A. Peripheral blood stem cell versus bone marrow transplantation: A perspective from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Exp Hematol 2016;44(7):567–73.

[38] Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood 2008;112(12):4371–83.

[39] Nakamura M, Arai Y, Hirabayashi S, et al. Residual disease is a strong prognostic marker in patients with acute lymphoblastic leukaemia with chemotherapy- refractory or relapsed disease prior to allogeneic stem cell transplantation. Br J Haematol 2021;194(2):403–13.

[40] Yeshurun M, Weisdorf D, Rowe JM, et al. The impact of the graft-versus-leu- kemia effect on survival in acute lymphoblastic leukemia. Blood Adv 2019;3 (4):670–80.

[41] Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-ver- sus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001;98 (10):2942–7.

[42] Bacigalupo A, Lamparelli T, Barisione G, et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late trans- plant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006;12(5):560–5.

[43] Finke J, Bethge WA, Schmoor C, et al. Standard graft-versus-host disease prophy- laxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 2009;10(9):855–64.

[44] Wang Y, Fu HX, Liu DH, et al. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical trans- plantation: a randomized trial. Bone Marrow Transplant 2014;49(3):426–33.

[45] Kroger N, Solano C, Wolschke C, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med 2016;374(1):43–53.

[46] Walker I, Panzarella T, Couban S, et al. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial. Lancet Haematol 2020;7(2):e100–11.

[47] Ofran Y, Beohou E, Labopin M, et al. Anti-thymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate- or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell trans- plantation in first complete remission—a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol 2019;184(4):643–6.

[48] Socie G, Schmoor C, Bethge WA, et al. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. Blood 2011;117(23):6375–82.

[49] Nagler A, Labopin M, Dholaria B, et al. Impact of antithymocyte globulin on out- comes of allogeneic hematopoietic cell transplantation with TBI. Blood Adv 2019;3(13):1950–60.

[50] Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol 2017;35(36):4003–11.

[51] Shiratori S, Sugita J, Fuji S, et al. Low-dose antithymocyte globulin inhibits chronic graft-versus-host disease in peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant 2021;56(9):2231–40.

[52] Nagler A, Labopin M, Shimoni A, et al. Mobilized peripheral blood stem cells com- pared with bone marrow as the stem cell source for unrelated donor allogeneic transplantation with reduced-intensity conditioning in patients with acute mye- loid leukemia in complete remission: an analysis from the Acute Leukemia Work- ing Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2012;18(9):1422–9.

[53] Fuji S, Miyamura K, Kanda Y, et al. Short-term clinical outcomes after HLA 1-locus mismatched uPBSCT are similar to that after HLA-matched uPBSCT and uBMT. Int J Hematol 2019;109(6):684–93.

[54] Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unre- lated donor. Japan Marrow Donor Program. N Engl J Med 1998;339(17):1177–85.

[55] Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015;21(3):389–401.

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る